Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

ResMed Inc.

RMD

ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.

Last trade $239.02
Day change +$0.83 (+0.35%)
Day range $234.13 – $241.18
Volume 527,834
Market cap $33.50B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$33.5B
Price / earnings
21.03×
Price / book
5.63×
Price / sales
5.84×
EV / sales
5.74×
EV / EBITDA
15.71×

Profitability

Earnings per share
$11.33
Return on assets
19.4%
Return on equity
26.79%
Dividend yield
1.07%

Liquidity and leverage

Debt / equity
0.07×
Current ratio
2.65×
Quick ratio
1.88×
Cash ratio
0.76×

Cash flow

Price / cash flow
18.92×
Price / free cash flow
20.82×
Free cash flow
$1.61B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RMD, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024
Revenue$1.41B$1.46B$1.43B$1.42B$1.34B$1.35B$1.29B$1.28B
Cost of revenue$544.25M$594.13M$532.58M$536.28M$517.92M$518.56M$517.88M$523.18M
Gross profit$870.57M$869.52M$898.83M$886.53M$817.66M$829.44M$773.85M$758.91M
Selling, general and administrative$314.72M$296.28M$285.66M$278.4M$281.65M$267.16M$245.3M$241.61M
Research and development$102.86M$105.73M$94.27M$90.97M$89.48M$86.44M$83.94M$81.37M
Total operating expenses$417.58M$420.81M$399.02M$394.87M$371.13M$374.9M$347.59M$341.67M
Operating income$452.98M$448.71M$499.81M$491.66M$446.54M$454.54M$426.27M$417.24M
Interest expense-$4.81M$20.89M$12.29M$0-$7.12M$5.76M$793K$0
Income before taxes$539.16M$474.16M$502.31M$496.15M$446.79M$458.05M$417.69M$418.32M
Income taxes$120.74M$90.73M$103.58M$103.56M$98.26M$78.35M$52.65M$73.7M
Net income$418.41M$383.43M$398.73M$392.59M$348.54M$379.71M$365.04M$344.62M
Net income attributable to common shareholders$418.41M$383.43M$398.73M$392.59M$348.54M$379.71M$365.04M$344.62M
EBITDA$494.73M$493.49M$558.79M$547.48M$494.24M$518.17M$469.94M$463.68M
Basic earnings per share$2.93$2.65$2.74$2.69$2.38$2.59$2.49$2.35
Diluted earnings per share$2.92$2.64$2.74$2.68$2.37$2.58$2.48$2.34

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

AASM releases roadmap to improve women’s sleep health

The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.

Zacks Investment Research

Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

Abbott reported Q3 2026 sales growth of 14.5% to $13.01 billion with broad-based strength across Established Pharmaceuticals, Medical Devices, and Diagnostics segments. The company announced plans to separate its Nutrition business into an independent publicly traded company by end of 2027. However, Abbott narrowed its 2026 sales growth guidance to 6% from 6.5-7.5% due to headwinds in Electrophysiology and Diabetes Care segments. The stock has outperformed peers and sector benchmarks over the past six months but is rated a Hold.

Zacks Investment Research

INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?

Inspire Medical Systems (INSP) shares gained 12.1% over three months despite a 7.9% revenue decline and 62.2% drop in adjusted Q3 EPS. Reimbursement issues cost the company $30M in Q3 revenues with a projected $120M full-year 2026 impact. The company targets low-single-digit revenue growth in 2027 through Project Horizon and battery replacement procedures, though reimbursement execution remains a key risk factor.

The Motley Fool

ResMed: 3 Key Takeaways for Long-Term Investors

ResMed reported 7% core revenue growth in Q1 FY2027 with expanding gross margins driven by manufacturing productivity gains. The company noted that patients on GLP-1 obesity medications are 11% more likely to adopt CPAP therapy for sleep apnea and show higher retention rates. ResMed returned over $1 billion to shareholders this quarter through dividends and share repurchases following the sale of its MatrixCare business, reflecting confidence in its 2030 strategy targeting high single-digit revenue growth with higher earnings growth.

Zacks Investment Research

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs

ResMed (RMD) delivered solid first-quarter fiscal 2027 results with adjusted EPS of $2.91, up 14% year-over-year and beating consensus by 9%. Revenues grew 6% to $1.41 billion, driven by sustained demand for sleep devices and masks. Gross margins expanded 50 basis points to 62.5% from productivity gains. However, the company faced headwinds from discontinued Astral life-support device sales and the MatrixCare divestiture. RMD maintained its fiscal 2027 guidance for 5-7% core constant-currency revenue growth and $12.00-$12.25 adjusted EPS.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Nov 12, 2026$0.66Dec 17, 2026recurring
Aug 20, 2026$0.66Sep 24, 2026recurring
May 14, 2026$0.60Jun 18, 2026recurring
Feb 12, 2026$0.60Mar 19, 2026recurring
Nov 13, 2025$0.60Dec 18, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 31, 20102-for-1forward split
Oct 3, 20052-for-1forward split